Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .
Menopause hormonal therapy in women with systemic lupus erythematosus.
OBJECTIVE To evaluate the effects of menopause hormonal therapy on disease activity in women with systemic lupus erythematosus ( SLE ) . METHODS We conducted a double-blind , r and omized clinical trial involving 106 women with SLE who were in the menopausal transition or in early or late postmenopause . Patients received a continuous-sequential estrogen-progestogen regimen ( n = 52 ) or placebo ( n = 54 ) . Disease activity was assessed at baseline and at 1 , 2 , 3 , 6 , 9 , 12 , 15 , 18 , 21 , and 24 months , according to the SLE Disease Activity Index ( SLEDAI ) . The primary outcome measure was global disease activity , estimated by measuring the area under the SLEDAI curve . Secondary outcome measures included maximum SLEDAI score , change in SLEDAI score , incidence of lupus flares , median time to flare , medication use , and adverse events . Results were studied using intent-to-treat analysis . RESULTS At baseline , demographic and disease characteristics were similar in both groups . Mean + /- SD SLEDAI scores were 3.5 + /- 3.3 and 3.1 + /- 3.4 in the menopause hormonal therapy and placebo groups , respectively ( P = 0.57 ) . Disease activity remained mild and stable in both groups throughout the trial . There were no significant differences between the groups in global or maximum disease activity , incidence or probability of flares , or medication use . Median time to flare was 3 months in both groups . Thromboses occurred in 3 patients who received menopause hormonal therapy and in 1 patient who received placebo . One patient in each group died during the trial due to sepsis . CONCLUSION Menopause hormonal therapy did not alter disease activity during 2 years of treatment . However , an apparently increased risk of thrombosis seems to be a real threat in women with SLE who receive menopausal hormone therapy
Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .